Scienmag

MARCH 11, 2021

A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants. Extremely preterm infants can suffer from a life-threatening inflammation of the gut.

Bacteria 72

Bacteria Bacterium Research Clinical Trials 72

Pharmaceutical Technology

OCTOBER 28, 2022

According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. The trial had two coprimary objectives, with one measuring the immunogenic response a month after the third dose, and the other doing the same after the fourth.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

XTalks

NOVEMBER 10, 2020

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. The vaccine is currently being tested in children in Phase III trials and the company is hoping to get FDA approval by the end of the year.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

pharmaphorum

OCTOBER 5, 2022

Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium. At the moment most cases are treated with azithromycin, with intravenous ceftriaxone generally reserved as a last-line therapy.

Vaccination 98

Vaccination Vaccine Immune Response Bacterium 98

Pharmaceutical Technology

SEPTEMBER 1, 2022

While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.

Manufacturing 130

Manufacturing Bacterium Reagent Production 130

pharmaphorum

OCTOBER 19, 2022

Now, Synlogic has reported phase 2 results of two non-absorbed strains of the bacterium Escherichia coli Nissle used as probiotics – codenamed SYNB1618 and SYNB1934 – which have been engineered to break down phe in the gastrointestinal tract.

Drugs 98

Drugs Bacterium Genetic Disease Sales 98

The Pharma Data

MARCH 21, 2022

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. That was surprising,” she said. The molecule has a small but complex ring structure.

Bacterium 52

Bacterium Scientist Clinical Trials Clinical Trials 52

pharmaphorum

JUNE 16, 2022

The Medicines and Healthcare products Regulatory Agency’s (MHRA) gave a conditional approval to Idefirix – an enzyme derived from the bacterium Streptococcus pyogenes that breaks down immunoglobulin G (IgG) antibodies in the body – in 2020. The post Hansa gets NICE okay for Idefirix in kidney transplant patients appeared first on.

Antibody 52

Antibody Bacterium Medicine Clinical Trials 52

XTalks

JULY 25, 2023

Anthrax is a rare, yet severe disease caused by the bacterium B. Moreover, the clinical trials demonstrated that Cyfendus exhibited a favorable tolerability profile. Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. What Is Anthrax? Additionally, at Day 64, 86.6

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

JANUARY 20, 2021

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). The antihistamine treatment is currently being evaluated in larger clinical trials.

Immune Response 52

Immune Response Research Allergies Protein 52

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 11, 2024

Zosurabalpin is highly effective against the bacterium carbapenem-resistant Acinetobacter baumannii (Crab), which is classified as a “priority 1” pathogen by the World Health Organization due to its growing presence in hospitals.

Bacterium 242

Bacterium Bacteria Drugs Research 242

pharmaphorum

MARCH 2, 2022

diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a phase 3 trial. The pharma company was quick to point out however that the CLOVER trial of PF-06425090 was undermined by a lower-than expected rate of C. billion play for Arena Pharma.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

Vaccination 105

Vaccination Vaccine Development Hormones 105

pharmaphorum

JULY 2, 2021

diff – a bacterium that causes diarrhoea and inflammation in the colon and is a major cause of illness and death worldwide – as well as other targets like inflammatory bowel disease. diff coming through clinical trials, some of which also have deep-pocketed partners. billion, but only included markets outside North America.

Bacterium 69

Bacterium Drugs Bacteria FDA Approval 69

pharmaphorum

DECEMBER 24, 2020

The US biotech will continue to provide support for two phase 2 trials of AMG 634 in TB and ENL which are due to get underway next year by producing and supplying the drug and funding the ENL trial. About a quarter of the world’s population carry the bacterium, and have a 5% to 15% chance of developing the disease.

Bacterium 52

Bacterium Licensing Licensing Development 52

The Pharma Data

NOVEMBER 26, 2020

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.?

Containment 52

Containment Bacterium Development Sales 52

pharmaphorum

JULY 14, 2021

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 1, 2025

Since then, I think it’s fair to say that most people have been nervous about the emergence of the next big infectious disease be that a virus, bacterium, fungus or parasite. (Sean Anthony Eddy/Getty Images) COVID emerged suddenly, spread rapidly and killed millions of people around the world.

Bacterium 246

Bacterium Clinical Trials Clinical Trials Clinical Research 246

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 4, 2024

In 1974, German chemist Axel Zeeck and his Turkish colleague Mithat Mardin showed red pigments produced by the bacterium Streptomyces […]

Scientist 240

Scientist Bacterium Engineer Drugs 240

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Phase I/II clinical trials to assess the use of the vaccine in paediatrics are planned to begin later this year. Phase III is expected to start in the short term.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Phase I/II clinical trials to assess the use of the vaccine in paediatrics are planned to begin later this year. Phase III is expected to start in the short term.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 11, 2024

A growing example of why collective efforts are needed is the rise in infections from Pseudomonas aeruginosa — a multi-drug-resistant bacterium. Companies like Merck and Entasis are advancing treatments like ETX0282C, which shows potential in Phase III trials. With treatments for these infections projected to grow from $2.34

Research 111

Research Bacteria Packaging Packaging 111

XTalks

DECEMBER 24, 2020

As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes. CRISPR Therapeutics.

Life Science 111

Life Science Vaccination Vaccine Gene 111